世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
 Antibody Drug Conjugates Market Report by Component (Monoclonal Antibodies, Linker, Cytotoxic Agent, and Others), Target (Antibody-Protein Toxin Conjugates, Antibody-Chelated Radionuclide Conjugates, Antibody-Small-Molecule Drug Conjugates, Antibody-Enzyme Conjugates), Application (Lymphoma, Ovarian Cancer, Lung Cancer, Breast Cancer, Brain Tumor, and Others), End User (Hospitals, Specialized Cancer Centers, Academic Research Institutes, Biotechnology Companies, and Others), and Region 2025-2033
The global antibody drug conjugates market size reached USD 9.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 50.2 Billion by 2033, exhibiting a growth rate (CAGR) o... もっと見る
英語原文をAIを使って翻訳しています。
SummaryThe global antibody drug conjugates market size reached USD 9.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 50.2 Billion by 2033, exhibiting a growth rate (CAGR) of 19.45% during 2025-2033.Antibody drug conjugates (ADCs) are highly potent biological drugs comprising tumor-targeting antibodies, which are chemically attached to a cytotoxic effector molecule. They deliver cytotoxic anticancer agents to affected cells by connecting them to monoclonal antibodies (mAb) through biodegradable linkers and allowing sensitive bifurcation between healthy and diseased tissues. They assist in increasing the cell-killing potential of mAb, enhancing drug tolerability, and limiting systematic exposure compared to standard chemotherapy bioactive compounds. At present, they are administered intravenously into the bloodstream to avoid gastric acid and proteolytic enzyme degradation of the mAb. Antibody Drug Conjugates Market Trends: Due to sedentary lifestyles and the rising number of individuals who smoke and drink regularly, there is an increase in the prevalence of cancer around the world. This, in confluence with the escalating demand for cost-effective and successful cancer treatments, represents one of the key factors bolstering the growth of the market. Apart from this, the existing linkers often release payloads nonspecifically and lead to off-target toxicity, which severely affects the development of ADCs. As a result, leading players are continuously funding their research and development (R&D) projects to optimize the existing chemical triggers and develop novel chemical triggers to generate highly selective linkers. They are also coming up with novel linker-antibody attachments to produce stable and homogenous ADCs and additional linker-payload attachments to allow the expansion of payloads. Moreover, they are focusing on improving the absorption, distribution, metabolism, and excretion, which is creating a favorable market outlook. Other major factors, including considerably improving healthcare infrastructure, increasing awareness about therapies available for cancer treatments, and the introduction of cleavable linker technology, are anticipated to propel the market growth. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global antibody drug conjugates market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on component, target, application and end user. Breakup by Component: ? Monoclonal Antibodies ? Linker ? Cytotoxic Agent ? Others Breakup by Target: ? Antibody-Protein Toxin Conjugates ? Antibody-Chelated Radionuclide Conjugates ? Antibody-Small-Molecule Drug Conjugates ? Antibody-Enzyme Conjugates Breakup by Application: ? Lymphoma ? Ovarian Cancer ? Lung Cancer ? Breast Cancer ? Brain Tumor ? Others Breakup by End User: ? Hospitals ? Specialized Cancer Centers ? Academic Research Institutes ? Biotechnology Companies ? Others Breakup by Region: ? North America o United States o Canada ? Asia-Pacific o China o Japan o India o South Korea o Australia o Indonesia o Others ? Europe o Germany o France o United Kingdom o Italy o Spain o Russia o Others ? Latin America o Brazil o Mexico o Others ? Middle East and Africa Competitive Landscape: The competitive landscape of the industry has also been examined along with the profiles of the key players being ADC Therapeutics SA, Astellas Pharma Inc., AstraZeneca plc, Celldex Therapeutics Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline Plc, ImmunoGen Inc, Pfizer Inc., Sanofi S.A., Seagen Inc., Sorrento Therapeutics Inc. and Takeda Pharmaceutical Company Ltd. Key Questions Answered in This Report: ? How has the global antibody drug conjugates market performed so far and how will it perform in the coming years? ? What has been the impact of COVID-19 on the global antibody drug conjugates market? ? What are the key regional markets? ? What is the breakup of the market based on the component? ? What is the breakup of the market based on the target? ? What is the breakup of the market based on the application? ? What is the breakup of the market based on the end user? ? What are the various stages in the value chain of the industry? ? What are the key driving factors and challenges in the industry? ? What is the structure of the global antibody drug conjugates market and who are the key players? ? What is the degree of competition in the industry? Table of Contents?1 Preface2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Antibody Drug Conjugates Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Component 6.1 Monoclonal Antibodies 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Linker 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Cytotoxic Agent 6.3.1 Market Trends 6.3.2 Market Forecast 6.4 Others 6.4.1 Market Trends 6.4.2 Market Forecast 7 Market Breakup by Target 7.1 Antibody-Protein Toxin Conjugates 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Antibody-Chelated Radionuclide Conjugates 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Antibody-Small-Molecule Drug Conjugates 7.3.1 Market Trends 7.3.2 Market Forecast 7.4 Antibody-Enzyme Conjugates 7.4.1 Market Trends 7.4.2 Market Forecast 8 Market Breakup by Application 8.1 Lymphoma 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Ovarian Cancer 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Lung Cancer 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Breast Cancer 8.4.1 Market Trends 8.4.2 Market Forecast 8.5 Brain Tumor 8.5.1 Market Trends 8.5.2 Market Forecast 8.6 Others 8.6.1 Market Trends 8.6.2 Market Forecast 9 Market Breakup by End User 9.1 Hospitals 9.1.1 Market Trends 9.1.2 Market Forecast 9.2 Specialized Cancer Centers 9.2.1 Market Trends 9.2.2 Market Forecast 9.3 Academic Research Institutes 9.3.1 Market Trends 9.3.2 Market Forecast 9.4 Biotechnology Companies 9.4.1 Market Trends 9.4.2 Market Forecast 9.5 Others 9.5.1 Market Trends 9.5.2 Market Forecast 10 Market Breakup by Region 10.1 North America 10.1.1 United States 10.1.1.1 Market Trends 10.1.1.2 Market Forecast 10.1.2 Canada 10.1.2.1 Market Trends 10.1.2.2 Market Forecast 10.2 Asia-Pacific 10.2.1 China 10.2.1.1 Market Trends 10.2.1.2 Market Forecast 10.2.2 Japan 10.2.2.1 Market Trends 10.2.2.2 Market Forecast 10.2.3 India 10.2.3.1 Market Trends 10.2.3.2 Market Forecast 10.2.4 South Korea 10.2.4.1 Market Trends 10.2.4.2 Market Forecast 10.2.5 Australia 10.2.5.1 Market Trends 10.2.5.2 Market Forecast 10.2.6 Indonesia 10.2.6.1 Market Trends 10.2.6.2 Market Forecast 10.2.7 Others 10.2.7.1 Market Trends 10.2.7.2 Market Forecast 10.3 Europe 10.3.1 Germany 10.3.1.1 Market Trends 10.3.1.2 Market Forecast 10.3.2 France 10.3.2.1 Market Trends 10.3.2.2 Market Forecast 10.3.3 United Kingdom 10.3.3.1 Market Trends 10.3.3.2 Market Forecast 10.3.4 Italy 10.3.4.1 Market Trends 10.3.4.2 Market Forecast 10.3.5 Spain 10.3.5.1 Market Trends 10.3.5.2 Market Forecast 10.3.6 Russia 10.3.6.1 Market Trends 10.3.6.2 Market Forecast 10.3.7 Others 10.3.7.1 Market Trends 10.3.7.2 Market Forecast 10.4 Latin America 10.4.1 Brazil 10.4.1.1 Market Trends 10.4.1.2 Market Forecast 10.4.2 Mexico 10.4.2.1 Market Trends 10.4.2.2 Market Forecast 10.4.3 Others 10.4.3.1 Market Trends 10.4.3.2 Market Forecast 10.5 Middle East and Africa 10.5.1 Market Trends 10.5.2 Market Breakup by Country 10.5.3 Market Forecast 11 SWOT Analysis 11.1 Overview 11.2 Strengths 11.3 Weaknesses 11.4 Opportunities 11.5 Threats 12 Value Chain Analysis 13 Porters Five Forces Analysis 13.1 Overview 13.2 Bargaining Power of Buyers 13.3 Bargaining Power of Suppliers 13.4 Degree of Competition 13.5 Threat of New Entrants 13.6 Threat of Substitutes 14 Price Analysis 15 Competitive Landscape 15.1 Market Structure 15.2 Key Players 15.3 Profiles of Key Players 15.3.1 ADC Therapeutics SA 15.3.1.1 Company Overview 15.3.1.2 Product Portfolio 15.3.1.3 Financials 15.3.2 Astellas Pharma Inc. 15.3.2.1 Company Overview 15.3.2.2 Product Portfolio 15.3.2.3 Financials 15.3.2.4 SWOT Analysis 15.3.3 AstraZeneca plc 15.3.3.1 Company Overview 15.3.3.2 Product Portfolio 15.3.3.3 Financials 15.3.3.4 SWOT Analysis 15.3.4 Celldex Therapeutics Inc. 15.3.4.1 Company Overview 15.3.4.2 Product Portfolio 15.3.4.3 Financials 15.3.4.4 SWOT Analysis 15.3.5 F. Hoffmann-La Roche AG 15.3.5.1 Company Overview 15.3.5.2 Product Portfolio 15.3.5.3 Financials 15.3.6 Gilead Sciences Inc. 15.3.6.1 Company Overview 15.3.6.2 Product Portfolio 15.3.6.3 Financials 15.3.6.4 SWOT Analysis 15.3.7 GlaxoSmithKline Plc 15.3.7.1 Company Overview 15.3.7.2 Product Portfolio 15.3.7.3 Financials 15.3.7.4 SWOT Analysis 15.3.8 ImmunoGen Inc 15.3.8.1 Company Overview 15.3.8.2 Product Portfolio 15.3.8.3 Financials 15.3.8.4 SWOT Analysis 15.3.9 Pfizer Inc. 15.3.9.1 Company Overview 15.3.9.2 Product Portfolio 15.3.9.3 Financials 15.3.9.4 SWOT Analysis 15.3.10 Sanofi S.A. 15.3.10.1 Company Overview 15.3.10.2 Product Portfolio 15.3.10.3 Financials 15.3.10.4 SWOT Analysis 15.3.11 Seagen Inc. 15.3.11.1 Company Overview 15.3.11.2 Product Portfolio 15.3.11.3 Financials 15.3.11.4 SWOT Analysis 15.3.12 Sorrento Therapeutics Inc. 15.3.12.1 Company Overview 15.3.12.2 Product Portfolio 15.3.12.3 Financials 15.3.13 Takeda Pharmaceutical Company Ltd. 15.3.13.1 Company Overview 15.3.13.2 Product Portfolio 15.3.13.3 Financials 15.3.13.4 SWOT Analysis List of Tables/GraphsList of FiguresFigure 1: Global: Antibody Drug Conjugates Market: Major Drivers and Challenges Figure 2: Global: Antibody Drug Conjugates Market: Sales Value (in Billion USD), 2019-2024 Figure 3: Global: Antibody Drug Conjugates Market Forecast: Sales Value (in Billion USD), 2025-2033 Figure 4: Global: Antibody Drug Conjugates Market: Breakup by Component (in %), 2024 Figure 5: Global: Antibody Drug Conjugates Market: Breakup by Target (in %), 2024 Figure 6: Global: Antibody Drug Conjugates Market: Breakup by Application (in %), 2024 Figure 7: Global: Antibody Drug Conjugates Market: Breakup by End User (in %), 2024 Figure 8: Global: Antibody Drug Conjugates Market: Breakup by Region (in %), 2024 Figure 9: Global: Antibody Drug Conjugates (Monoclonal Antibodies) Market: Sales Value (in Million USD), 2019 & 2024 Figure 10: Global: Antibody Drug Conjugates (Monoclonal Antibodies) Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 11: Global: Antibody Drug Conjugates (Linker) Market: Sales Value (in Million USD), 2019 & 2024 Figure 12: Global: Antibody Drug Conjugates (Linker) Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 13: Global: Antibody Drug Conjugates (Cytotoxic Agent) Market: Sales Value (in Million USD), 2019 & 2024 Figure 14: Global: Antibody Drug Conjugates (Cytotoxic Agent) Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 15: Global: Antibody Drug Conjugates (Other Components) Market: Sales Value (in Million USD), 2019 & 2024 Figure 16: Global: Antibody Drug Conjugates (Other Components) Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 17: Global: Antibody Drug Conjugates (Antibody-Protein Toxin Conjugates) Market: Sales Value (in Million USD), 2019 & 2024 Figure 18: Global: Antibody Drug Conjugates (Antibody-Protein Toxin Conjugates) Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 19: Global: Antibody Drug Conjugates (Antibody-Chelated Radionuclide Conjugates) Market: Sales Value (in Million USD), 2019 & 2024 Figure 20: Global: Antibody Drug Conjugates (Antibody-Chelated Radionuclide Conjugates) Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 21: Global: Antibody Drug Conjugates (Antibody-Small-Molecule Drug Conjugates) Market: Sales Value (in Million USD), 2019 & 2024 Figure 22: Global: Antibody Drug Conjugates (Antibody-Small-Molecule Drug Conjugates) Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 23: Global: Antibody Drug Conjugates (Antibody-Enzyme Conjugates) Market: Sales Value (in Million USD), 2019 & 2024 Figure 24: Global: Antibody Drug Conjugates (Antibody-Enzyme Conjugates) Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 25: Global: Antibody Drug Conjugates (Lymphoma) Market: Sales Value (in Million USD), 2019 & 2024 Figure 26: Global: Antibody Drug Conjugates (Lymphoma) Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 27: Global: Antibody Drug Conjugates (Ovarian Cancer) Market: Sales Value (in Million USD), 2019 & 2024 Figure 28: Global: Antibody Drug Conjugates (Ovarian Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 29: Global: Antibody Drug Conjugates (Lung Cancer) Market: Sales Value (in Million USD), 2019 & 2024 Figure 30: Global: Antibody Drug Conjugates (Lung Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 31: Global: Antibody Drug Conjugates (Breast Cancer) Market: Sales Value (in Million USD), 2019 & 2024 Figure 32: Global: Antibody Drug Conjugates (Breast Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 33: Global: Antibody Drug Conjugates (Brain Tumor) Market: Sales Value (in Million USD), 2019 & 2024 Figure 34: Global: Antibody Drug Conjugates (Brain Tumor) Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 35: Global: Antibody Drug Conjugates (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024 Figure 36: Global: Antibody Drug Conjugates (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 37: Global: Antibody Drug Conjugates (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024 Figure 38: Global: Antibody Drug Conjugates (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 39: Global: Antibody Drug Conjugates (Specialized Cancer Centers) Market: Sales Value (in Million USD), 2019 & 2024 Figure 40: Global: Antibody Drug Conjugates (Specialized Cancer Centers) Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 41: Global: Antibody Drug Conjugates (Academic Research Institutes) Market: Sales Value (in Million USD), 2019 & 2024 Figure 42: Global: Antibody Drug Conjugates (Academic Research Institutes) Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 43: Global: Antibody Drug Conjugates (Biotechnology Companies) Market: Sales Value (in Million USD), 2019 & 2024 Figure 44: Global: Antibody Drug Conjugates (Biotechnology Companies) Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 45: Global: Antibody Drug Conjugates (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024 Figure 46: Global: Antibody Drug Conjugates (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 47: North America: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024 Figure 48: North America: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 49: United States: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024 Figure 50: United States: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 51: Canada: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024 Figure 52: Canada: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 53: Asia-Pacific: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024 Figure 54: Asia-Pacific: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 55: China: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024 Figure 56: China: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 57: Japan: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024 Figure 58: Japan: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 59: India: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024 Figure 60: India: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 61: South Korea: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024 Figure 62: South Korea: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 63: Australia: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024 Figure 64: Australia: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 65: Indonesia: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024 Figure 66: Indonesia: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 67: Others: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024 Figure 68: Others: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 69: Europe: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024 Figure 70: Europe: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 71: Germany: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024 Figure 72: Germany: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 73: France: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024 Figure 74: France: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 75: United Kingdom: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024 Figure 76: United Kingdom: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 77: Italy: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024 Figure 78: Italy: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 79: Spain: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024 Figure 80: Spain: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 81: Russia: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024 Figure 82: Russia: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 83: Others: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024 Figure 84: Others: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 85: Latin America: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024 Figure 86: Latin America: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 87: Brazil: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024 Figure 88: Brazil: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 89: Mexico: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024 Figure 90: Mexico: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 91: Others: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024 Figure 92: Others: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 93: Middle East and Africa: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024 Figure 94: Middle East and Africa: Antibody Drug Conjugates Market: Breakup by Country (in %), 2024 Figure 95: Middle East and Africa: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033 Figure 96: Global: Antibody Drug Conjugates Industry: SWOT Analysis Figure 97: Global: Antibody Drug Conjugates Industry: Value Chain Analysis Figure 98: Global: Antibody Drug Conjugates Industry: Porter's Five Forces Analysis List of Tables Table 1: Global: Antibody Drug Conjugates Market: Key Industry Highlights, 2024 and 2033 Table 2: Global: Antibody Drug Conjugates Market Forecast: Breakup by Component (in Million USD), 2025-2033 Table 3: Global: Antibody Drug Conjugates Market Forecast: Breakup by Target (in Million USD), 2025-2033 Table 4: Global: Antibody Drug Conjugates Market Forecast: Breakup by Application (in Million USD), 2025-2033 Table 5: Global: Antibody Drug Conjugates Market Forecast: Breakup by End User (in Million USD), 2025-2033 Table 6: Global: Antibody Drug Conjugates Market Forecast: Breakup by Region (in Million USD), 2025-2033 Table 7: Global: Antibody Drug Conjugates Market: Competitive Structure Table 8: Global: Antibody Drug Conjugates Market: Key Players
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療）の最新刊レポート
IMARC Services Private Limited.社の 医療分野 での最新刊レポート
本レポートと同じKEY WORD（antibody）の最新刊レポート
よくあるご質問IMARC Services Private Limited.社はどのような調査会社ですか?インドに調査拠点を持つ調査会社。幅広い分野をカバーしていますがケミカルに特に焦点を当てています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
